Converting enzyme determines plasma clearance of angiotensin-(1-7)

Hypertension

Volumn 32, Issue 3, 1998, Pages 496-502

  Yamada, Kazuo ^a   Iyer, Shridhar N ^a   Chappell, Mark C ^a   Ganten, Detlev ^b   Ferrario, Carlos M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Angiotensin (1 7); Angiotensin converting enzyme; Blood pressure; Lisinopril; Losartan; Rats, inbred SHR; Rats, transgenic

Indexed keywords

ANGIOTENSIN; DIPEPTIDYL CARBOXYPEPTIDASE; LISINOPRIL; LOSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPONTANEOUSLY HYPERTENSIVE RAT;

EID: 0031683009     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.32.3.496     Document Type: Article

References (49)

1. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI. Counterregulatory actions of angiotensin-(1-7). Hypertension. 1997;30: 535-541.
2. DelliPizzi A, Hilchey SD, Bell-Quilley CP. Natriuretic actions of angiotensin-(1-7). Br J Pharmacol. 1994;111:1-3.
3. 2 release. Hypertension. 1995;25:1238-1244.
4. Handa RK, Ferrario CM, Strandhoy JW. Renal actions of angiotensin-(1-7) in vivo and in vitro studies. Am J Physiol. 1996;270: F141-F147.
5. Forster C, le Tran Y. Angiotensin-(1-7) and the rat aorta: modulation by the endothelium. J Cardiovasc Pharmacol. 1997;30:676-682.
6. Porsti I, Bara AT, Busse R, Hecker M. Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium: implications for a novel angiotensin receptor. Br J Pharmacol. 1994;111:652-654.
7. Brosnihan KB, Li P, Ferrario CM. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension. 1996;27: 523-528.
8. Osei SY, Ahima RS, Minkes RK, Weaver JP, Khosla MC, Kadowitz PJ. Differential responses to angiotensin-(1-7) in the feline mesenteric and hindquarters vascular beds. Eur J Pharmacol. 1993;234:35-42.
9. Paula RD, Lima CV, Khosla MC, Santos RAS. Angiotensin-(1-7) potentiates the hypotensive effect of bradykinin in conscious rats. Hypertension. 1995;26:1154-1159.
10. Benter IF, Diz DI, Ferrario CM. Pressor and reflex sensitivity is altered in spontaneously hypertensive rats treated with angiotensin-(1-7). Hypertension. 1995;26:1138-1144.
11. Campagnole-Santos MJ, Heringer SB, Batista EN, Khosla MC, Santos RAS. Differential baroreceptor reflex modulation by centrally infused angiotensin peptides. Am J Physiol. 1992;263:R89-R94.
12. Oliveira DR, Santos RAS, Santos GFP, Khosla MC, Campagnole-Santos MJ. Changes in the baroreflex control of heart rate produced by central infusion of selective angiotensin antagonists in hypertensive rats. Hypertension. 1996;27:1284-1290.
13. Benter IF, Ferrario CM, Morris M, Diz DI. Antihypertensive actions of angiotensin-(I-7) in spontaneously hypertensive rats. Am J Physiol (Heart Circ Physiol). 1995;269:H313-H319.
14. Moriguchi A, Tallant EA, Matsumura K, Reilly TM, Walton H, Ganten D, Ferrario CM. Opposing actions of Angiotensin-(1-7) and Angiotensin II in the brain of transgenic hypertensive rats. Hypertension. 1995;25:1260-1265.
15. Lima CV, Paula RD, Resende FL, Khosla MC, Santos RAS. Potentiation of the hypotensive effect of bradykinin by short-term infusion of angiotensin-(1-7) in normotensive and hypertensive rats. Hypertension. 1997; 30:542-548.
16. Okolicany J, McEnroe GH, Koh GY, Lewiski JA, Maack T. Clearance receptor and neutral endopeptidase-mediated metabolism of atrial natriuretic factor. Am J Physiol. 1992;263:F546-F553.
17. Almeida FA, Suzuki RM, Scarborough RM, Lewicki JA, Maack T. Clearance function of type C receptors of atrial natriuretic factor in rats. Am J Physiol. 1989;256:R469-R479.
18. Ashwell G, Harford J. Carbohydrate-specific receptors in the liver. Annu Rev Biochem. 1982;51:531-534.
19. Golstein JL, Brown MS. The low-density lipoprotein pathway and its relation to atherosclerosis. Annu Rev Biochem. 1977;81:382-395.
20. Chappell MC, Pirro NT, Sykes A, Ferrario CM. Metabolism of angiotensin-(1-7) by angiotensin converting enzyme. Hypertension. 1998;31: 362-367.
21. Li P, Chappell MC, Ferrario CM, Brosnihan KB. Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension. 1997;29:394-400.
22. Deddish PA, Marcic B, Jackman HL, Wang H-Z, Skidgel RA, Erdös EG. N-domain specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin-(1-7) and Keto-ACE. Hypertension. 1998;31:912-917.
23. Lawrence AC, Clark IJ, Campbell DJ. Increased angiotensin-(1-7) in hypophysial-portal plasma of conscious sheep. Neuroendocrinology. 1992;55:105-114.
24. Campbell DJ, Lawrence AC, Towrie A, Kladis A, Valentijn AJ. Differential regulation of angiotensin peptide levels in plasma and kidney of the rat. Hypertension. 1991;18:763-773.
25. Kohara K, Brosnihan KB, Chappell MC, Khosla MC, Ferrario CM. Angiotensin-(1-7): a member of circulating angiotensin peptides. Hypertension. 1991;17:131-138.
26. Kohara K, Brosnihan KB, Ferrario CM. Angiotensin-(1-7) in the spontaneously hypertensive rat. Peptides. 1993;14:883-891.
27. Luque M, Martin P, Martell N, Fernandez C, Brosnihan KB, Ferrario CM. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J Hypertens. 1996;14:799-805.
28. Senanayake PD, Moriguchi A, Kumagai H, Ganten D, Ferrario CM, Brosnihan KB. Increased expression of angiotensin peptides in the brain of transgenic hypertensive rats. Peptides. 1994;15:919-926.
29. Iyer SN, Chappell MC, Averill DB, Diz DI, Ferrario CM. Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension. 1998;31:699-705.
30. Benter IF, Diz DI, Ferrario CM. Cardiovascular actions of angiotensin-(1-7). Peptides. 1993;14:679-684.
31. Kohara K, Tabuchi Y, Senanayake P, Brosnihan KB, Ferrario CM. Reassessment of plasma angiotensins measurement: effects of protease inhibitors and sample handling procedures. Peptides. 1991;12: 1135-1141.
32. Vernace MA, Mento PF, Maita ME, Wilkes BM. Effects of angiotensin receptor subtype inhibitors on plasma angiotensin clearance. Hypertension. 1994;23:853-856.
33. 2 receptors in the plasma clearance of angiotensin II. J Cardiovasc Pharmacol. 1998;31:464-469.
34. Naden RP, Coultrup S, Arant BS, Rosenfeld CR. Metabolic clearance of angiotensin II in pregnant and non pregnant sheep. Am J Physiol (Endocrinol Metab). 1985;249:E49-E55.
35. Nakamoto H, Ferrario CM, Fuller SB, Robaczwski DL, Winicov E, Dean RH. Angiotensin-(1-7) and nitric oxide interaction in renovascular hypertension. Hypertension. 1995;25:796-802.
36. Chappell MC, Brosnihan KB, Welches WR, Ferrario CM. Characterization by high performance liquid chromatography of angiotensin peptides in the plasma and cerebrospinal fluid of the dog. Peptides. 1987;8:939-942.
37. 1) receptor-mediated accumulation of angiotensin II in tissues and its intracellular half-life in vivo. Hypertension. 1997;30:42-49.
38. Champlain JD, Genest J, Veyratt R, Boucher R. Factors controlling renin in man. Arch Intern Med. 1966;117:355-363.
39. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JM, Smith RD. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993; 45:205-251.
40. Iyer SN, Ferrario CM, Chappell MC. Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension. 1998;31:356-361.
41. Cachofeiro V, Maeso R, Rodrigo E, Navarro J, Ruilope LM, Lahera V. Nitric oxide and prostaglandins in the prolonged effects of losartan and ramipril in hypertension. Hypertension. 1995;26:236-243.
42. Pucci ML, Tong X, Miller KB, Guan H, Nasjletti A. Calcium- and protein kinase C-dependent basal tone in the aorta of hypertensive rats. Hypertension. 1995;25:752-757.
43. Tallant EA, Lu X, Weiss RB, Chappell MC, Ferrario CM. Bovine aortic endothelial cells contain an angiotensin-(1-7) receptor. Hypertension. 1997;29:388-392.
44. Erdos EG. Angiotensin I converting enzyme and the changes in our concepts through the years. Hypertension. 1992;16:363-370.
45. 2 receptors and angiotensin I-converting enzyme in CHO cells. Circ Res. 1997;81:848-856.
46. Cerpa-Poljak A, Lahnstein J, Mason KE, Smythe GA, Duncan MW. Mass spectrometric identification and quantification of hemorphins extracted from human adrenal and pheochromocytoma tissue. J Neurochem. 1997; 68:1712-1719.
47. Decarie A, Raymond P, Gervais N, Couture R, Adam A. Serum interspecies differences in metabolic pathways of bradykinin and [des-Arg9]BK: influence of enalaprilat. Am J Physiol. 1997;271: H1340-H1347.
48. Kelm M, Schrader J. Control of coronary vascular tone by nitric oxide. Circ Res. 1990;66:1561-1575.
49. Ignarro LJ. Endothelium-derived nitric oxide: actions and properties. FASEB J. 1989;3:31-36.